<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of Lyme disease*</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of Lyme disease*</h1>
<div class="graphic"><div class="figure"><div class="ttl">Treatment of Lyme disease*</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="18%"></colgroup><colgroup width="28%"></colgroup> <tbody> <tr> <td class="subtitle1"> </td> <td class="subtitle1">Drug</td> <td class="subtitle1">Adult dose</td> <td class="subtitle1">Pediatric dose</td> <td class="subtitle1">Comment</td> </tr> <tr> <td class="subtitle2_left" colspan="5">Erythema migrans (early disease)</td> </tr> <tr> <td class="indent1" rowspan="3"> </td> <td><span class="nowrap_whitespace">Doxycycline<sup>¶</sup><sup>Δ</sup><sup>◊</sup></span></td> <td>100 mg orally twice daily for 10 days</td> <td>4.4 mg/kg/day orally divided twice daily (maximum 100 mg per dose) for 10 days</td> <td rowspan="3"> <ul> <li>Patients with early disseminated disease who present with multiple erythema migrans lesions are treated the same way as those with a single erythema migrans lesion.</li> <li>For patients unable to tolerate the preferred regimens, alternative treatments include: <ul> <li>Azithromycin (in adults: 500 mg orally once daily; in children: 10 mg/kg/day [maximum 500 mg per dose]) for 7 days (range 5 to 10 days); <strong>or</strong></li> <li>Clarithromycin (in adults: 500 mg orally twice daily; in children: 15 mg/kg/day divided twice daily [maximum 500 mg per dose]) for 14 to 21 days.</li> </ul> </li> </ul> </td> </tr> <tr> <td><strong>or</strong> Amoxicillin</td> <td>500 mg orally 3 times daily for 14 days</td> <td>50 mg/kg/day orally divided 3 times daily (maximum 500 mg per dose) for 14 days</td> </tr> <tr> <td><strong>or</strong> Cefuroxime axetil</td> <td>500 mg orally twice daily for 14 days</td> <td>30 mg/kg/day orally divided twice daily (maximum 500 mg per dose) for 14 days</td> </tr> <tr> <td class="subtitle2_left" colspan="5">Neurologic disease<sup>§</sup></td> </tr> <tr> <td class="indent1">Acute neurologic disease, such as: <ul class="decimal_heading"> <li>Cranial nerve palsy (eg, facial nerve palsy)</li> <li>Meningitis</li> <li>Radiculoneuropathy (early disseminated disease)</li> </ul> </td> <td><span class="nowrap_whitespace">Doxycycline<sup>¶</sup><sup>Δ</sup><sup>◊</sup></span></td> <td>100 mg orally twice daily for 14 to 21 days</td> <td>4.4 mg/kg/day orally divided twice daily (maximum 100 mg per dose) for 14 to 21 days</td> <td rowspan="2"> <ul> <li>For patients with isolated facial nerve palsy (eg, no evidence of meningitis or radiculoneuropathy), amoxicillin or cefuroxime is an alternative in patients with contraindications to doxycycline. For patients with other forms of acute neurologic disease, most experts would initiate IV therapy (eg, ceftriaxone) if doxycycline cannot be used.</li> <li>In the United States, most practitioners favor using longer courses of antibiotics (eg, 28 days) for those with evidence of severe neurologic disease.</li> </ul> </td> </tr> <tr> <td class="indent1">Severe neurologic disease, including encephalitis</td> <td><span class="nowrap_whitespace">Ceftriaxone<sup>¥</sup><sup>‡</sup></span></td> <td>2 g IV once daily for 14 to 28 days</td> <td>50 to 75 mg/kg IV once daily (maximum 2 g per dose) for 14 to 28 days</td> </tr> <tr> <td class="subtitle2_left" colspan="5">Carditis</td> </tr> <tr> <td class="indent1" rowspan="3">Mild (eg, asymptomatic patients with first-degree atrioventricular block and PR interval &lt;300 milliseconds)</td> <td><span class="nowrap_whitespace">Doxycycline<sup>¶</sup><sup>Δ</sup><sup>◊</sup></span></td> <td>100 mg orally twice daily for 14 to 21 days</td> <td>4.4 mg/kg/day orally divided twice daily (maximum 100 mg per dose) for 14 to 21 days</td> <td rowspan="3"> </td> </tr> <tr> <td><strong>or</strong> Amoxicillin</td> <td>500 mg orally 3 times daily for 14 to 21 days</td> <td>50 mg/kg/day orally divided 3 times daily (maximum 500 mg per dose) for 14 to 21 days</td> </tr> <tr> <td><strong>or</strong> Cefuroxime axetil</td> <td>500 mg orally twice daily for 14 to 21 days</td> <td>30 mg/kg/day orally divided twice daily (maximum 500 mg per dose) for 14 to 21 days</td> </tr> <tr> <td class="indent1">More serious disease (eg, symptomatic, second- or third-degree atrioventricular block, first-degree atrioventricular block with PR interval ≥300 milliseconds)</td> <td><span class="nowrap_whitespace">Ceftriaxone<sup>¥</sup><sup>‡</sup></span></td> <td>2 g IV once daily for 14 to 21 days</td> <td>50 to 75 mg/kg IV once daily (maximum 2 g per dose) for 14 to 21 days</td> <td> <ul> <li>A parenteral antibiotic regimen is recommended for initial treatment for hospitalized patients. IV antibiotics should be continued until high-grade atrioventricular block has resolved and the PR interval has become less than 300 milliseconds. The patient may then be switched to oral therapy to complete a 14- to 21-day course.</li> <li>A temporary pacemaker may be necessary for some patients with carditis.</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="5">Arthritis</td> </tr> <tr> <td class="indent1" rowspan="2">Initial <span class="nowrap_whitespace">treatment<sup>†</sup></span></td> <td><span class="nowrap_whitespace">Doxycycline<sup>¶</sup><sup>◊</sup></span></td> <td>100 mg orally twice daily for 28 days</td> <td>≥8 years: 4.4 mg/kg/day orally divided twice daily (maximum 100 mg per dose) for <span class="nowrap_whitespace">28 days<sup>◊</sup></span></td> <td rowspan="2"> <ul> <li>Cefuroxime is a suitable alternative in patients with contraindications to doxycycline and amoxicillin, although it has not been assessed in clinical studies for this indication.</li> </ul> </td> </tr> <tr> <td><strong>or</strong> Amoxicillin</td> <td>500 mg orally 3 times daily for 28 days</td> <td>50 mg/kg/day orally divided 3 times daily (maximum 500 mg per dose) for 28 days</td> </tr> <tr> <td class="indent1" rowspan="3">Persistent arthritis with little or no response to oral antibiotics (despite adequate prior oral therapy)</td> <td><span class="nowrap_whitespace">Ceftriaxone<sup>¥</sup></span></td> <td>2 g IV once daily for 14 to 28 days</td> <td>50 to 75 mg/kg IV once daily (maximum 2 g per dose) for 14 to 28 days</td> <td rowspan="3"> <ul> <li>IV therapy should be administered to patients who presented with moderate-to-severe arthritis and had minimal or no response to oral therapy.</li> <li>Retreatment with a second course of oral therapy can be used for those with persistent arthritis who initially presented with mild arthritis (even if there is a minimal response to therapy) as well as those with moderate-to-severe disease who had a partial response to oral therapy. If there is an incomplete response after the second course of oral treatment, then IV therapy should be administered.</li> <li>For patients who fail to respond to oral and IV therapy, the use of disease-modifying antirheumatic drugs or arthroscopic synovectomy may be indicated.</li> </ul> </td> </tr> <tr> <td><strong>or</strong> <span class="nowrap_whitespace">Doxycycline<sup>¶</sup><sup>◊</sup></span></td> <td>100 mg orally twice daily for 28 days</td> <td>≥8 years: 4.4 mg/kg/day orally divided twice daily (maximum 100 mg per dose) for <span class="nowrap_whitespace">28 days<sup>◊</sup></span></td> </tr> <tr> <td><strong>or</strong> Amoxicillin</td> <td>500 mg orally 3 times daily for 28 days</td> <td>50 mg/kg/day orally divided 3 times daily (maximum 500 mg per dose) for 28 days</td> </tr> <tr> <td class="subtitle2_left" colspan="5">Acrodermatitis chronica atrophicans</td> </tr> <tr> <td class="indent1" rowspan="3"> </td> <td><span class="nowrap_whitespace">Doxycycline<sup>¶</sup><sup>◊</sup></span></td> <td>100 mg orally twice daily for 21 to 28 days</td> <td>4.4 mg/kg/day orally divided twice daily (maximum 100 mg per dose) for 21 to <span class="nowrap_whitespace">28 days<sup>◊</sup></span></td> <td> </td> </tr> <tr> <td><strong>or</strong> Amoxicillin</td> <td>500 mg orally 3 times daily for 21 to 28 days</td> <td>50 mg/kg/day orally divided 3 times daily (maximum 500 mg per dose) for 21 to 28 days</td> <td> </td> </tr> <tr> <td><strong>or</strong> Cefuroxime</td> <td>500 mg orally twice daily for 21 to 28 days</td> <td>30 mg/kg/day orally divided twice daily (maximum 500 mg per dose) for 21 to 28 days</td> <td> </td> </tr> </tbody></table></div><div class="graphic_lgnd">This table is meant for use with UpToDate content on Lyme disease. Refer to UpToDate content for additional details on management of special populations (eg, pediatric and pregnant patients) and management of those with persistent symptoms after treatment.</div><div class="graphic_footnotes"><p>IV: intravenous.</p>
<p>* A complete response to treatment may be delayed beyond the treatment duration, regardless of the clinical manifestation of Lyme disease. However, in most patients with persistent symptoms the duration of treatment should not be extended.</p>
<p>¶ For pregnant and lactating patients, tetracyclines are generally avoided in favor of a beta-lactam (eg, amoxicillin, cefuroxime). In the setting of neurologic disease or contraindication to a beta-lactam, the decision to use doxycycline must be decided on a case-by-case basis. Although most tetracyclines are contraindicated in pregnancy because of the risk of hepatotoxicity in the mother and potential adverse effects on fetal bone and teeth, limited data suggest these events are extremely rare with doxycycline when short courses are used.</p>
<p>Δ Doxycycline also has activity against coinfections such as <em>Anaplasma phagocytophilum</em> and <em>Borrelia miyamotoi</em> but not against <em>Babesia microti</em>.</p>
<p>◊ The American Academy of Pediatrics supports the use of doxycycline for children &lt;8 years of age if it is administered for ≤21 days. However, the data on safety of doxycycline in this population are limited, and some providers still prefer a beta-lactam rather than doxycycline unless there is evidence of neurologic disease or infection with <em>Anaplasma</em>. Studies have not evaluated the safety of doxycycline in children &lt;8 years of age when the duration of treatment is &gt;21 days (eg, Lyme arthritis).</p>
<p>§ For patients with neurologic disease, there are no studies to help guide length of therapy within the range suggested by the guidelines, and there are no diagnostic tests to determine clearance of infection or predict the success of therapy.</p>
<p>¥ Alternative IV agents include cefotaxime 2 g IV every 8 hours for 14 to 28 days for adults and 150 to 200 mg/kg/day in 3 divided doses (maximum 6 g per day) for children, or penicillin G 18 to 24 million units per day divided into doses given every 4 hours in adults and 200,000 to 400,000 units/kg/day divided every 4 hours (maximum 18 to 24 million units per day) in children.</p>
<p>‡ Doxycycline can be used in patients intolerant of beta-lactam antibiotics.</p>
† On rare occasion, patients may present with late-stage neurologic disease and arthritis. In this setting, IV therapy is usually preferred for initial treatment.</div><div class="graphic_reference">Adapted from:
<ol>
<li>Lantos PM, Rumbaugh J, Bockenstedt LK, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis, and Treatment of Lyme Disease. Arthritis Rheumatol 2021; 73:12.</li>
<li>Sanchez E, Vannier E, Wormser GP, Hu LT, et al. Diagnosis, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: a review. JAMA 2016; 315:1767.</li>
<li>American Academy of Pediatrics. Lyme disease. In: Red Book: 2018 Report of the Committee on Infectious Diseases, 31st ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, 2018. p.515.</li>
</ol></div><div id="graphicVersion">Graphic 59949 Version 12.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
